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ABSTRACT
Objectives: Few nationwide population-based studies
have examined the burden of asthma during
pregnancy. Here, we investigated the burden and
medical treatment of asthma during pregnancy
requiring healthcare utilisation in South Korea.
Design: Cohort study.
Setting: Nationwide insurance claims database.
Participants: A total of 1 306 281 pregnant women
who delivered in South Korea in 2009–2011.
Outcomes: The prevalence and exacerbation rates of
asthma requiring healthcare utilisation, and the
prescription of antiasthmatic drugs during pregnancy.
Results: The prevalence of asthma requiring
healthcare utilisation was 0.43% among pregnant
women. Among those with asthma requiring healthcare
utilisation, 6.9% were hospitalised and treated with
systemic steroids and short-acting β2-agonists during
pregnancy. Oral drugs were prescribed less during the
third trimester than during the first trimester (all p
values for trends were <0.001). A significant number of
patients with asthma were likely to stop taking
antiasthmatic drugs after becoming pregnant.
Conclusions: The prevalence of asthma requiring
healthcare utilisation during pregnancy was not very
high. However, a significant number of women were
likely to stop taking antiasthmatic drugs, and those
who did tended to experience exacerbations.
INTRODUCTION
Asthma is an important health condition
during pregnancy. Approximately 8% of
pregnant women in the USA currently have
asthma, and 4.1% of them experience at
least one asthma attack.1 One prospective
study also reported that the majority of preg-
nant women who seek respiratory specialist
care for dyspnoea are asthmatics or probable
asthmatics.2 Asthma seems to increase the
risk of low birth weight, pre-eclampsia,3
preterm delivery and congenital malforma-
tions.4 Patients with asthma are also
susceptible to drug safety issues. For
example, treatment with systemic corticoster-
oids during asthma could increase the risk of
pre-eclampsia, low birth weight and preterm
delivery.5 Although several studies have
reported that inhaled corticosteroids (ICSs)
and β-agonists did not affect pregnancy out-
comes,5–8 many women commonly avoid
taking asthma drugs during pregnancy
because of these safety issues.9 10
However, few nationwide population-based
studies have been performed of the actual
burden and treatment of asthma during preg-
nancy.1 The national insurance programme
of South Korea covers more than 95% of
Koreans. Although the prevalence of asthma
among people aged 20–39 years is reportedly
0.5–2%,11 12 that of asthma among pregnant
women has never been investigated. In this
study, we investigated the prevalence of
asthma requiring healthcare utilisation
during pregnancy in South Korea, incidence
of severe asthma exacerbations and actual
medical treatment of these patients using a
nationwide insurance claims database.
Strengths and limitations of this study
▪ A study analysing asthma requiring healthcare
utilisation during pregnancy using a large-scale
nationwide database.
▪ The diagnosis of asthma was defined as its
International Classification of Diseases 10th
Edition code together with the patient’s use of
antiasthmatic medication.
▪ The results showed that a significant number of
patients were likely to stop taking drugs after
becoming pregnant and that the prescription of
oral drugs decreased during pregnancy.
▪ Although only a portion of the asthmatic preg-
nant women required healthcare utilisation, our
results showed a real-world healthcare utilisation
pattern of asthmatics during pregnancy.




The Health Insurance Review and Assessment Service
(HIRA, Seoul, Republic of Korea) is a governmental
agency that examines the accuracy of claims submitted
to the National Health Insurance (NHI) and National
Medical Aid (NMA) in South Korea, which covers
approximately 96.6% of the entire 48.6 million South
Korean population. We used the HIRA database, which
includes information regarding demographic variables
and all of the rendered medical services along with diag-
nostic codes (International Statistical Classiﬁcation of
Diseases and Related Health Problems, 10th Edition
code, ICD-10), and all of the dispensed prescribed medi-
cations. The proportion of missing or out-of-range
answers in terms of key ﬁelds, including drug names,
quantity, date dispensed and duration, comprised <0.5%
of the records.13 Written informed consent was not
required due to the study’s retrospective nature. Patient
records and information were anonymised and
de-identiﬁed prior to the analysis.
Analyses
We identiﬁed a pregnancy whenever a claim about a
delivery event was found. The initiation pregnancy date
was calculated as the date 40 weeks before the delivery
event. If a woman was pregnant more than once, only
the ﬁrst pregnancy was included in the analysis. In our
study, we focused on patients with asthma who required
healthcare utilisation (who visited hospitals and
received a physician’s diagnosis and care). To increase
the diagnostic accuracy and reduce bias, asthma was
deﬁned in two ways: (1) deﬁnition 1: ICD-10 code J45
or J46 that was repeated with at least a 1 month inter-
val; and (2) deﬁnition 2: deﬁnition 1 plus use of any
asthma medication at least once. Asthma medication
included ICSs, ICS combined with inhaled long-acting
β-agonists (ICS/LABAs), inhaled short-acting β-agonists
(SABAs), leukotriene receptor antagonists (LTRAs) and
theophylline.
The prevalence of asthma requiring healthcare utilisa-
tion during pregnancy was calculated as the number of
asthma cases per 100 pregnancies (%). We also esti-
mated the incidence rates of severe exacerbations of
asthma (number of cases per pregnancy). We deﬁned
severe exacerbations in two ways: (1) a visit to the emer-
gency room or hospitalisation with a diagnosis of asthma
and (2) condition 1 plus treatment with systemic corti-
costeroids or SABAs. Asthma medications prescribed
within 14 weeks before the initiation date of pregnancy
and those prescribed during each pregnancy trimester
were also evaluated. We evaluated whether there were
signiﬁcant trends across trimesters in the use of medica-
tions using Mantel-Haenszel statistics.14 All analyses were
performed using SAS 9.2 software (SAS Institute, Cary,
North Carolina, USA) and Stata V.13.1 software
(StataCorp, College Station, Texas, USA).
RESULTS
A total of 1 306 281 pregnant women (mean age, 30.62
±4.49 years) were observed in 2009–2011. Of them, 5589
were diagnosed with asthma (deﬁnition 1 prevalence of
0.43% in 2009–2010: 0.44% in 2009, 0.41% in 2010).
Among them, 3825 were prescribed asthma drugs at
least once during pregnancy (deﬁnition 2 prevalence of
0.29% in 2009–2010: 0.29% in 2009 and 0.28% in 2010).
Table 1 shows how many pregnant women with asthma
experienced exacerbations. Among the total number of
pregnant women with asthma requiring healthcare util-
isation, 11.6% visited the emergency department or
were admitted to the hospital for asthma treatment
(incidence, 0.17 per pregnancy) and 6.9% were treated
with systemic steroids and SABA after visiting the emer-
gency department or hospitalised for asthma treatment
(incidence, 0.09 per pregnancy). Among the pregnant
women with asthma who were treated with asthma medi-
cations, 16% visited the emergency department or were
hospitalised for asthma treatment (incidence, 0.23 per
pregnancy) and 10% were treated with systemic steroids
and SABA after visiting the emergency department or
being hospitalised for asthma treatment (incidence, 0.13
per pregnancy).
More than half of the pregnant women with asthma
were prescribed either ICS/LABA (27.9%) or ICS alone
(25.2%). The most commonly prescribed ICS/LABA was
ﬂuticasone/salmeterol (19.2%), while the most com-
monly used ICS was budesonide (22.1%). LTRA, theo-
phylline and systemic steroids were used in 29%, 9.2%
and 9.1% of cases, respectively. These oral drugs were
less prescribed during the third trimester than during
the ﬁrst trimester (all p values for trends were <0.001;
table 2).
To evaluate how patients with asthma changed their
treatment compliance after pregnancy, we also analysed
82 710 patients from the overall cohort who were diag-
nosed with asthma (ICD-10 code J45-J46 on at least one
occasion) within 2 years before pregnancy. Compared
with the period within 14 weeks just before pregnancy,
the date of asthma medication use during pregnancy
was markedly decreased (table 3).
DISCUSSION
This study showed a prevalence of asthma requiring
healthcare utilisation during pregnancy of 0.43% in
South Korea. In a ﬁeld survey conducted more than
10 years ago of a randomly recruited general population
from cities and rural areas in Korea, the prevalence of
current asthma, deﬁned as current wheezing and posi-
tive bronchial hyper-responsiveness, in participants aged
≤39 years was approximately 2%.12 Considering that
only a small percentage of patients seek healthcare ser-
vices, the prevalence in our study may be reasonable.
The prevalence of asthma during pregnancy was com-
parable to or slightly lower than that in the previous
report in which, on the basis of the insurance database,
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the prevalence of asthma in the Korean general popula-
tion aged 20–39 years was reportedly 4.65–6.73 cases per
1000 persons.11
Signiﬁcant numbers of pregnant women with asthma
experienced severe exacerbations in our study. Among
the women who were diagnosed with asthma, 11.6%
visited the emergency room or were admitted to a hos-
pital for asthma treatment, while 6.9% were also treated
with systemic steroids and SABA, ﬁndings that are con-
sistent with the results of previous studies.15–18 This
ﬁnding could be associated with the general low rate of
asthma medication use during pregnancy. Among the
82 710 patients with suspected asthma who were diag-
nosed with asthma within 2 years before pregnancy, only
4.9% were prescribed asthma drugs at least once. The
most common drugs prescribed for asthma during







Definition 1: Among all pregnant women with asthma
In the complete study period (n=5589; 0.43% among all pregnant women)
(1) ER visit or hospitalisation for asthma treatment 647 (11.6%) 926 0.17
(2) Condition 1+treatment with systemic steroids or SABA 383 (6.9%) 506 0.09
In 2009 (n=1986; 0.44% of all pregnant women)
(1) ER visit or hospitalisation due to asthma 223 (11.2%) 324 0.16
(2) Condition 1+treatment with systemic steroids or SABA 127 (6.4%) 170 0.09
In 2010 (n=1864; 0.41% of all pregnant women)
(1) ER visit or hospitalisation for asthma treatment 213 (11.4%) 318 0.16
(2) Condition 1+treatment with systemic steroids or SABA 132 (7.1%) 184 0.09
Definition 2: Definition 1 and treatment with antiasthmatic drugs
In the complete study period (n=3825; 0.29% of all pregnant women)
(1) ER visit or hospitalisation due to asthma 613 (16%) 886 0.23
(2) Condition 1+treatment with systemic steroids or SABA 383 (10%) 506 0.13
In 2009 (n=1325; 0.29% of all pregnant women)
(1) ER visit or hospitalisation for asthma treatment 213 (16.1%) 313 0.24
(2) Condition 1+treatment with systemic steroids or SABA 127 (9.6%) 170 0.13
In 2010 (n=1274; 0.28% of all pregnant women)
(1) ER visit or hospitalisation due to asthma 201 (15.8%) 305 0.23
(2) Condition 1+treatment with systemic steroids or SABA 132 (10.4%) 184 0.14
ER, emergency room; SABA, short-acting β2-agonists.
Table 2 Asthma treatment among pregnant women with asthma (n=5589)
Total 1st trimester 2nd trimester 3rd trimester
P for trendn (%) n (%) n (%) n (%)
ICS or LABA 0.678
Neither ICS nor LABA 2581 (46.2) 4084 (73.1) 3968 (71) 4060 (72.6)
LABA only 41 (0.7) 17 (0.3) 16 (0.3) 14 (0.3)
ICS without LABA 1407 (25.2) 633 (11.3) 730 (13.1) 663 (11.9)
ICS with LABA 1560 (27.9) 855 (15.3) 875 (15.7) 852 (15.2)
ICS/LABA
Fluticasone/salmeterol 1071 (19.2) 599 (10.7) 574 (10.3) 550 (9.8) 0.127
Budesonide/formoterol 569 (10.2) 272 (4.9%) 319 (5.7%) 314 (5.6%) 0.079
ICS
Fluticasone 74 (1.3) 30 (0.5) 39 (0.7) 41 (0.7) 0.198
Budesonide 1236 (22.1) 550 (9.8) 626 (11.2) 574 (10.3) 0.458
Other ICS 115 (2.1) 57 (1) 67 (1.2) 55 (1) 0.854
LABA
Salmeterol 40 (0.7) 17 (0.3) 16 (0.3) 13 (0.2) 0.470
Formoterol 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 0.221
SABA 1805 (32.3) 901 (16.1) 924 (16.5) 772 (13.8) 0.001
LTRA 1620 (29) 1081 (19.3) 675 (12.1) 516 (9.2) <0.001
Theophylline 515 (9.2) 283 (5.1) 159 (2.8) 105 (1.9) <0.001
Systemic steroids 509 (9.1) 301 (5.4) 214 (3.8) 201 (3.6) <0.001
ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LTRA, leukotriene receptor antagonists; SABA, short-acting β2-agonists.
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pregnancy in South Korea were ICS or ICS/LABA,
similar to those administered to non-pregnant patients
with asthma. When ICS alone was used, budesonide was
more commonly selected during pregnancy than ﬂutica-
sone, although ﬂuticasone/salmeterol was more widely
chosen than budesonide/formoterol. This phenomenon
might be inﬂuenced by the result of a subgroup analysis
of a randomised controlled trial in which the safety of
budesonide during pregnancy was demonstrated.7
The adherence rate with prescription drugs is relatively
low,19 20 and pregnant women with asthma are no excep-
tion.21 22 In our study, many women may have stopped
taking antiasthmatic drugs after becoming pregnant, pos-
sibly due to concerns that they could affect pregnancy
outcomes. In fact, the US Food and Drug Administration
categorises the majority of asthma drugs including ﬂuti-
casone, salmeterol, ﬂuticasone/salmeterol, formoterol,
budesonide/formoterol, salbutamol, theophylline and
prednisolone into category C (risk not ruled out).
However, it is widely accepted that it is safer for pregnant
women with asthma to be treated with asthma medica-
tions than continuing to have asthma symptoms and
exacerbations.23 Although no drug can be considered
completely safe,10 the major antiasthmatic drugs are gen-
erally considered safe5–8 and uncontrolled asthma may
be associated with poorer pregnancy outcomes.3 4 18 In
fact, the guidelines state that poorly controlled asthma
and exacerbations put babies at much greater risk than
do current asthma treatments.24 In our study, a signiﬁ-
cant number of women were likely to stop antiasthmatic
drugs and a substantial number of pregnant women with
asthma did experience exacerbations, which might indir-
ectly support the guidelines’ emphasis on the adherence
for asthma treatment during pregnancy.
The limitations of our study include that only a portion
of our pregnant cohort had asthma requiring healthcare
utilisation. Since this study was based on a claims database
and not a survey, some pregnant women with mild or
well-controlled asthma who did not need to seek medical
attention may not have been included in the analysis. It is
well known that similar percentages of women have
improved, unchanged and worsened asthmatic symptoms
during pregnancy.25 In addition, pregnant women who
were not covered by NHI or NMA were not included in
this study. Moreover, our data should be cautiously inter-
preted. First, the analyses of asthma treatment adherence
and severe asthma exacerbation used different cohorts.
Second, we cannot differentiate between physician pre-
scribing behaviours and patient adherence. Therefore, as
mentioned above, the association between poor asthma
treatment adherence and the signiﬁcant number of
severe exacerbations during pregnancy cannot be consid-
ered a causal relationship.
In conclusion, in this analysis of a nationwide insurance
claims database, the prevalence of asthma requiring
healthcare utilisation during pregnancy was not very high.
However, a signiﬁcant number of women were likely to
stop antiasthmatic drugs and experienced exacerbations.
Careful management and further studies are needed to
increase asthma treatment adherence during pregnancy.
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